Professor Sir Nicholas J White
Podcast interview
Malaria kills more than half a million people every year. Following a number of groundbreaking clinical trials, Professor Sir Nick White and his Thailand team successfully demonstrated the effectiveness of artemisinin drug therapy for malaria in adults, children and infants. He also pioneered artemisinin combination therapy, the first-line treatment for malaria worldwide.
Research groups
Colleges
Nicholas White
FRS
Professor of Tropical Medicine
- Professor at Mahidol University in Thailand
Professor White’s diverse interests include the epidemiology, pathophysiology and management of uncomplicated and severe malaria, meliodosis, enteric fever, tetanus, dengue haemorrhagic fever, Japanese encephalitis and tuberculosis. His particular interests at present include the pathophysiology and treatment of severe malaria, the prevention of antimalarial drug resistance using artemisinin-based combinations. and the biology of relapse in vivax malaria.
Vivax malaria
Recent publications
-
Triple artemisinin-based combination therapies for malaria: proceed with caution - Authors' reply.
van der Pluijm RW. et al, (2021), Lancet (London, England), 396, 1976 - 1977
-
Improving statistical power in severe malaria genetic association studies by augmenting phenotypic precision.
Watson JA. et al, (2021), eLife, 10
-
Bactericidal activities and post-antibiotic effects of ofloxacin and ceftriaxone against drug-resistant Salmonella enterica serovar Typhi.
Wain J. et al, (2021), The Journal of antimicrobial chemotherapy
-
SERCAP: is the perfect the enemy of the good?
White NJ. and Nosten FH., (2021), Malaria journal, 20
-
Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial.
McLean ARD. et al, (2021), The Lancet. Infectious diseases